| International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, ... Biology of Blood and Marrow Transplantation 22 (1), 4-10, 2016 | 626 | 2016 |
| Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis E Lefebvre, G Moyle, R Reshef, LP Richman, M Thompson, F Hong, ... PloS one 11 (6), e0158156, 2016 | 337 | 2016 |
| Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial CA Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... The lancet oncology 23 (1), 91-103, 2022 | 329 | 2022 |
| Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease R Reshef, SM Luger, EO Hexner, AW Loren, NV Frey, SD Nasta, ... New England Journal of Medicine 367 (2), 135-145, 2012 | 291 | 2012 |
| Prospective, randomized, double-blind, phase III clinical trial of anti–T-lymphocyte globulin to assess impact on chronic graft-versus-host disease–free survival in patients … RJ Soiffer, HT Kim, J McGuirk, ME Horwitz, L Johnston, MM Patnaik, ... Journal of Clinical Oncology 35 (36), 4003, 2017 | 281 | 2017 |
| An early-biomarker algorithm predicts lethal graft-versus-host disease and survival MJ Hartwell, U Özbek, E Holler, AS Renteria, H Major-Monfried, P Reddy, ... JCI insight 2 (3), 2017 | 235 | 2017 |
| Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder★ R Reshef, S Vardhanabhuti, MR Luskin, DF Heitjan, D Hadjiliadis, S Goral, ... American Journal of Transplantation 11 (2), 336-347, 2011 | 233 | 2011 |
| Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc … J Bolaños-Meade, R Reshef, R Fraser, M Fei, S Abhyankar, Z Al-Kadhimi, ... The Lancet Haematology 6 (3), e132-e143, 2019 | 228 | 2019 |
| MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD H Major-Monfried, AS Renteria, A Pawarode, P Reddy, F Ayuk, E Holler, ... Blood, The Journal of the American Society of Hematology 131 (25), 2846-2855, 2018 | 189 | 2018 |
| The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder MR Luskin, DS Heil, KS Tan, S Choi, EA Stadtmauer, SJ Schuster, ... American Journal of Transplantation 15 (10), 2665-2673, 2015 | 163 | 2015 |
| Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) C Jacobson, JC Chavez, AR Sehgal, BM William, J Munoz, G Salles, ... Blood 136, 40-41, 2020 | 135 | 2020 |
| HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis M Gooptu, R Romee, A St. Martin, M Arora, M Al Malki, JH Antin, ... Blood, The Journal of the American Society of Hematology 138 (3), 273-282, 2021 | 106 | 2021 |
| Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity S He, Y Liu, L Meng, H Sun, Y Wang, Y Ji, J Purushe, P Chen, C Li, ... Nature communications 8 (1), 2125, 2017 | 98 | 2017 |
| Pediatric‐inspired therapy compared to allografting for P hiladelphia chromosome‐negative adult ALL in first complete remission MD Seftel, D Neuberg, MJ Zhang, HL Wang, KK Ballen, J Bergeron, ... American journal of hematology 91 (3), 322-329, 2016 | 85 | 2016 |
| Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis J Bolaños-Meade, M Hamadani, J Wu, MM Al Malki, MJ Martens, ... New England Journal of Medicine 388 (25), 2338-2348, 2023 | 84 | 2023 |
| Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide SR McCurdy, MJ Zhang, A St. Martin, MM Al Malki, A Bashey, S Gaballa, ... Blood advances 2 (3), 299-307, 2018 | 82 | 2018 |
| The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease HK Srinagesh, U Özbek, U Kapoor, F Ayuk, M Aziz, K Ben-David, ... Blood advances 3 (23), 4034-4042, 2019 | 81 | 2019 |
| COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood cancer discovery 1 (3), 234-243, 2020 | 80 | 2020 |
| Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome BC Shaffer, KW Ahn, ZH Hu, T Nishihori, AK Malone, D Valcárcel, ... Journal of Clinical Oncology 34 (16), 1864, 2016 | 74 | 2016 |
| Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis RH Moy, AP Huffman, LP Richman, L Crisalli, XK Wang, JA Hoxie, R Mick, ... Blood, The Journal of the American Society of Hematology 129 (7), 906-916, 2017 | 73 | 2017 |
Daniel F. HeitjanSMU/UTSWPotvrđena adresa e-pošte na smu.edu
